GET DAILY SIGNALSiRhythm Holdings (IRTC) Drops 12.4% After Q3 Profit Beat
Key Takeaways
- Third quarter 2026 revenue rose 14.9% year over year to $221.6 million, roughly in line with the analyst consensus of about $222.3 million.
- Adjusted (non-GAAP) earnings per share (EPS) reached $0.82, far above the roughly $0.05 analysts had expected, driven by a sharp margin expansion.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed to $51.18 million, a 23.1% margin that nearly doubled the consensus estimate.
- Full-year revenue guidance was raised to $890 million–$895 million, but the midpoint still came in below Wall Street's forecast, contributing to the stock's decline.
- On a GAAP (Generally Accepted Accounting Principles) basis, the company posted a net loss as a one-time litigation settlement charge weighed on results.
Earnings Context and Why It Matters
iRhythm Holdings is a digital healthcare company known for its Zio cardiac monitoring platform, and its quarterly results offer a read on demand for ambulatory heart monitoring across cardiology, primary care, and international markets. This report carries added weight because it is the first since the company closed its acquisition of VitalConnect, broadening its portfolio into mobile cardiac telemetry (MCT), a form of continuous heart-rhythm monitoring. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors were also watching whether the company could sustain the momentum of recent quarters, when revenue growth and margin improvement consistently outpaced expectations. The reaction to the report shows that strong profit execution alone was not enough to satisfy a market focused on the forward revenue trajectory.
Reported Results
iRhythm Holdings reported third quarter 2026 revenue of $221.6 million, up 14.9% year over year and essentially in line with the consensus estimate of about $222.3 million. Adjusted (non-GAAP) EPS came in at $0.82, a substantial beat versus the roughly $0.05 analysts had modeled, and a dramatic improvement from a loss of $0.06 per share in the prior-year quarter.
Profitability was the standout theme. Adjusted EBITDA reached $51.18 million, representing a 23.1% margin, well above the $27.82 million consensus. Gross margin expanded to 74.2%, up roughly 310 basis points from a year earlier, helped by volume growth, operational efficiencies, and a one-time tariff refund benefit.
However, the bottom line on a GAAP basis swung to a net loss of approximately $29.9 million, or $0.90 per diluted share, reflecting a one-time litigation settlement charge of about $49.8 million. For the full year, management raised revenue guidance to a range of $890 million–$895 million (up from a prior midpoint of $885 million) and guided adjusted EBITDA margin to 15.5%–16.0%. The updated revenue midpoint of $892.5 million remained roughly 1.5% below consensus, a key source of investor disappointment. The guidance includes about $16 million of expected VitalConnect revenue contribution through year-end.
Market Reaction and Investor Sentiment
Despite a significant earnings beat on the bottom line, iRhythm Holdings shares fell roughly 12.4% following the report. The decline highlights how the market weighed the company's conservative full-year revenue outlook against the strong quarterly profit performance. Investors appear to have focused on the gap between the raised guidance midpoint and the higher consensus forecast, as well as the one-time litigation charge that pushed GAAP results into a loss. The closing of the VitalConnect acquisition was framed by management as a long-term growth opportunity, but the near-term contribution embedded in guidance was more modest than some investors had hoped. Overall, sentiment reflects a tension between improving operational profitability and questions about the pace of future revenue growth.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether iRhythm Holdings can close the gap between its guidance and Street expectations while continuing to expand margins. Management guided full-year revenue of $890 million–$895 million and an adjusted EBITDA margin of 15.5%–16.0%, with the VitalConnect integration expected to add about $16 million in revenue through the end of 2026.
Several factors will shape the coming quarters. First, the pace of Zio Monitor volume growth across care settings remains central, since demand has consistently exceeded internal expectations. Second, the integration of VitalConnect and its FDA-cleared MCT device will be a key test of management's ability to broaden its cardiac-monitoring portfolio without disrupting core execution.
Margin trajectory is another area to monitor, particularly whether gross-margin gains from automation and scale can be sustained without one-time benefits. Finally, the one-time litigation settlement and any related regulatory or legal developments could continue to influence reported GAAP results and cash flow. Operating cash flow came in at just $4.44 million in the quarter, leaving liquidity and expense discipline as important watchpoints heading into the fourth quarter.
Using Tickeron AI Tools in My Research
I often turn to Tickeron’s AI Screener when evaluating healthcare names like this one. It lets me quickly filter for stocks showing similar technical patterns or fundamental trends, which helps put quarterly results in broader context without spending hours on manual screens. The tool has become a regular part of how I cross-check ideas before forming a fuller view on names in the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRTC's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for IRTC turned positive on October 15, 2026. Looking at past instances where IRTC's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on IRTC as a result. In 68 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
IRTC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IRTC crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRTC advanced for three days, in 254 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
IRTC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IRTC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: IRTC's P/B Ratio (23.750) is slightly higher than the industry average of (4.338). IRTC's P/E Ratio (-319.048) is considerably lower than the industry average of (1.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (4.398) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. IRTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Is the 80-20 Rule the Key to Efficiency? Exploring the Pareto Principle
What is Form 706 GS (D): Generation Skipping Transfer Tax Return for Distributions?
What is the Ascending Triangle (Bearish) Pattern?
Is the 50/30/20 Budget Rule the Key to Financial Success?
What Is American Association of Retired Persons?
General Information
a provider of monitoring and diagnostic solutions for detection of cardiac arrhythmias
Industry MedicalNursingServices
Advertisement